New drug combo aims to shrink rectal tumors before surgery
NCT ID NCT07291401
Summary
This study is testing if adding a new two-drug immunotherapy (QL1706) to standard chemotherapy and radiation is more effective at shrinking rectal tumors before surgery. About 108 patients with locally advanced rectal cancer will be randomly assigned to receive either the standard treatment or the standard treatment plus the immunotherapy. The main goal is to see if the new combination leads to more patients having their tumors disappear completely, which could potentially allow some to avoid major surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.